News NICE green light a win for Lilly in RA market RA drug backed after manufacturer offered discount.
News Kisqali set for approval - but likely to hit same NICE obsta... Concerns that NICE will reject Kisqali like it did Ibrance.
News Gottlieb outlines FDA plan to keep generics cheap Reports also suggest Trump's pricing plans may be pro-industry.
Views & Analysis Immuno-oncology drugs: key to the Cancer Moonshot? Assessing the global challenges inhibiting immuno-oncology market access.
News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News Lilly strikes again, buying CAR-T firm Orna for $2.4bn In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
